Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspective

Virology Journal

Adhemar Longatto-Filho¹  Kari J. Syrjänen³  Adriana T. Lorenzi² 

[1] ICVS/3B’s – PT Government Associate laboratory, Braga, Portugal;Molecular Oncology Center, Barretos Cancer Hospital, Barretos, Brazil;Biohit HealthCare Oyj, Helsinki, Finland

关键词: Pap test;    Cancer screening;    Molecular diagnostic techniques;    HPV DNA test;    Cervical cancer;   

Others  :  1224537
DOI  :  10.1186/s12985-015-0342-0

 received in 2015-02-03, accepted in 2015-07-13,  发布年份 2015

【 摘 要 】

This review tackles the issues related to disease burden caused by cervical cancer (CC) and its precursor (CIN) lesions in Brazil. A special focus is given to new technologies with potential to interfere with the development of CC by reducing the high-risk human papillomavirus (hr-HPV)-induced lesions that remain a major public health burden in all developing countries where organized screening programs do not exist. Globally, 85 % of all incident CC and 50 % of CC deaths occur in the developing countries. Unfortunately, most regions of Brazil still demonstrate high mortality rates, ranking CC as the second most common cancer among Brazilian women. Recently, CC screening programs have been tailored in the country to enable early detection of CC precursor lesions and thereby reduce cancer mortality. A combination of HPV testing with liquid-based cytology (LBC) seems to be a promising new approach in CC screening, with high expectation to offer an adequate control of CC burden in this country.

【 授权许可】

   
2015 Lorenzi et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, Poljak M. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Pannonica Adriat. 2011; 20:113-23.
• [2]Bernard HU, Burk RD, Chen Z, van Doorslaer K, Zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010; 401:70-9.
• [3]Syrjänen K, Syrjänen S: Papillomavirus Infections in Human Pathology. 1st ed. NY, USA: J.Wiley & Sons; 2000.
• [4]Coelho FRGF, J. Fregnani J.H.T.G. Zeferino, L.C. Villa, L.L. Federico, M.H. Novaes, P.E.R.S. Costa, R.L.R. Câncer do Colo do Útero. São Paulo,Brazil: Tecmedd; 2008.
• [5]GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. http://globocan.iarc.fr/Default.aspx. Accessed 05 Jan 2015.
• [6]Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012; 30 Suppl 5:F55-70.
• [7]Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111:145-53.
• [8]Crawford R, Grignon AL, Kitson S, Winder DM, Ball SL, Vaughan K, Stanley MA, Sterling JC, Goon PK. High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology. BMC Cancer. 2011; 11:473. BioMed Central Full Text
• [9]Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103:368-83.
• [10]Sakakibara N, Chen D, McBride AA. Papillomaviruses use recombination-dependent replication to vegetatively amplify their genomes in differentiated cells. PLoS Pathog. 2013; 9: Article ID e1003321
• [11]Gross G, Tyring SK. Sexually transmitted infections and sexually transmitted diseases. Springer, Heidelberg; 2011.
• [12]Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006; 61:S3-14.
• [13]Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M et al.. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013; 31 Suppl 7:H1-31.
• [14]Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 Suppl 10:K29-41.
• [15]Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011; 121:4593-9.
• [16]Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol. 2007; 107:S19-23.
• [17]Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009; 101:1612-23.
• [18]Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110:525-41.
• [19]Kajitani N, Satsuka A, Kawate A, Sakai H. Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. Front Microbiol. 2012; 3:152.
• [20]Campos KL, Machado AP, Almeida FG, Bonin CM, Prata TT, Almeida LZ, Padovani CT, Ferreira AM, Fernandes CE, Tozetti IA. Good agreements between self and clinician-collected specimens for the detection of human papillomavirus in Brazilian patients. Mem Inst Oswaldo Cruz. 2014; 109:352-5.
• [21]Syrjänen K, Hakama M, Saarikoski S, Väyrynen M, Yliskoski M, Syrjänen S, Kataja V, Castrén O. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis. 1990; 17:15-9.
• [22]Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K, Mulherkar R. HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One. 2012; 7: Article ID e41012
• [23]Oh Y, Bae SM, Kim YW, Choi HS, Nam GH, Han SJ, Park CH, Cho Y, Han BD, Ahn WS. Polymerase chain reaction-based fluorescent Luminex assay to detect the presence of human papillomavirus types. Cancer Sci. 2007; 98:549-54.
• [24]Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 Suppl 5:F12-23.
• [25]INCA: Instituto Nacional do Câncer/ National Cancer Institute (Cancer in Brazil: data from population-base records). Câncer no Brasil: dados dos registros de base populacional. 2014. [http://www.inca.gov.br/cancernobrasil/2010]. Acessed 20 Nov 2014.
• [26]WHO: Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 20 Nov 2014.
• [27]WHO: Cervical Cancer - Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 20 Nov 2014.
• [28]WHO: Comprehensive Cervical Cancer Control - A guide to essential practice., 2nd edition: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/144785/1/9789241548953_eng.pdf. Accessed 20 Nov 2014.
• [29]IARC. International Agency for Research on Cancer. Human Papillomavirus and Related Cancer in Brazil. Summary Report 2010. http://screening.iarc.fr/doc/Human%20Papillomavirus%20and%20Related%20Cancers.pdf. Accessed 20 Nov 2014.
• [30]MS/INCA. Ministério da Saúde e Instituto Nacional do Câncer [Health Ministry and National Institute of Cancer] (Brazilian guidelines for screening of cervical cancer). Diretrizes brasileiras para rastreamento do câncer de colo do útero. 2011. http://bvsms.saude.gov.br/bvs/publicacoes/inca/rastreamento_cancer_colo_utero.pdf. Accessed 08 Jan 2015.
• [31]Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008; 113:1980-93.
• [32]Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357:1579-88.
• [33]Stormo AR, de Moura L, Saraiya M. Cervical cancer-related knowledge, attitudes, and practices of health professionals working in Brazil’s network of primary care units. Oncologist. 2014; 19:375-82.
• [34]Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine. 2008; 26 Suppl 1:A16-23.
• [35]Saúde MMoHMd: HPV vaccination. In Blog of Health/Blog da Saúde, 2015. http://www.blog.saude.gov.br/index.php/35256-sus-oferta-vacina-contra-hpv-para-meninas-de-9-a-11-anos. Accessed 10 Mar 2015.
• [36]Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet. 2014; 383:493-4.
• [37]Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH et al.. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014; 15:172-83.
• [38]Navarro C, Fonseca AJ, Sibajev A, Souza CI, Araújo DS, Teles DA, Carvalho SG, Cavalcante KW, Rabelo WL. Cervical cancer screening coverage in a high-incidence region. Rev Saude Publica. 2015; 49:17.
• [39]Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012; 30:3044-50.
• [40]Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ et al.. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012; 104:178-88.
• [41]Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010; 11:1160-71.
• [42]Castle PE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012; 30 Suppl 5:F117-22.
• [43]Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011; 378:1868-73.
• [44]Lorenzi AT, Fregnani JH, Possati-Resende JC, Neto CS, Villa LL, Longatto-Filho A. Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test. Gynecol Oncol. 2013; 131:131-4.
• [45]Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol. 2007; 105:530-5.
• [46]Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008; 19:342-54.
• [47]Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol. 2010; 21:448-58.
• [48]Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R et al.. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008; 100:492-501.
• [49]Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010; 21:1693-700.
• [50]Longatto-Filho A, Schmitt FC. Gynecological cytology: too old to be a pop star but too young to die. Diagn Cytopathol. 2007; 35:672-3.